-
Sign This Letter!
This letter provided by FARA (Friedreich’s Ataxia Research Alliance) is addressed to FDA & Reata Pharmaceuticals to allow individuals with Friedreich’s Ataxia access to Omaveloxolone, a new clinically proven drug that slows down the progression of FA.
This letter requests Reata to submit a New Drug Application (NDA) on an urgent basis and FDA to exercise the flexibility granted by law and contained in FDA guidance in considering approval of an NDA for Omavaloxolone in FA based on the existing evidence from clinical trials.
The effects of this drug will help significantly slow down our progression by improving the symptoms of detexerity, walking, speech and fatigue levels improved.
To sign, click here: http://www.curefa.org/advocacy
-
0 Replies
Sorry, there were no replies found.
Log in to reply.